Abstract
Large cell neuroendocrine carcinomas (CNEGC) are rare tumors of high-grade malignancy and poor prognosis. The management of metastatic CNEGC is complex and based on a low level of evidence. Recent advances on the molecular alterations (mutations of the TP53, RB1, STK11, KEAP1 genes) that can guide the type of chemotherapy and that affect the efficacy of immunotherapy are reported in this article. The prospective evaluation of immunotherapy in combination or as monotherapy on first-line in metastatic stages remains a challenge.© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
